Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | AGER | Q15109 | 5/20 | 0.41 |
| ▸ | PDE2A | O00408 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283384 | 1.00 | DRD2 (0.47) | DRD2DRD3AGERPDE2AKDM4E | |
| SCHEMBL1283229 | 1.00 | DRD2 (0.47) | DRD2DRD3AGERPDE2AKDM4E | |
| SCHEMBL1283499 | 0.98 | DRD2 (0.45) | DRD2DRD3AGERPDE2AACHE | |
| SCHEMBL13372533 | 0.94 | DRD3 (0.44) | DRD2DRD3AGERPDE2A | |
| SCHEMBL1283710 | 0.93 | HRH3 (0.42) | DRD2DRD3AGERPDE2AACHE | |
| SCHEMBL1283509 | 0.93 | HRH3 (0.42) | DRD2DRD3AGERPDE2AACHE | |
| SCHEMBL1283440 | 0.93 | DRD3 (0.46) | DRD2DRD3AGERPDE2AACHE | |
| SCHEMBL1283320 | 0.93 | DRD2 (0.43) | DRD2DRD3AGERPDE2AACHE | |
| SCHEMBL1283477 | 0.93 | AGER (0.41) | DRD2DRD3AGERPDE2A | |
| SCHEMBL1282905 | 0.92 | DRD2 (0.40) | DRD2DRD3AGERKDM4EGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | DRD2 4691/4885DRD3 4321/4885AGER 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.